IDNAiShares Genomics Immunology and Healthcare ETF

Grow my money7y track recordRanked #982 of 3,055 in this goal

Tracks the investment results of an index composed of developed and emerging market companies benefiting from growth in genomics, immunology, and bioengineering.

By iShares · Launched 2019

Annual Cost

0.47%

#2,464 of 6,040 · average

Fund Size

$257M

#2,236 of 6,040 · mid-size

Return (1Y)

+77.6%

Track Record

7 years

#1,903 of 6,040 · established

Performance

Total-return NAV · USD

Growth of $10,000

$17,414+74.1%

Total-return NAV, USD. Net of fund fees, before tax.

What's inside

How Beacon categorizes this fund

Asset class

Equity

Region

Global

Cap

Multi cap

Strategy

Index tracking

Sector

Health care

Focus

Biotech & Genomics

Index tracked

NYSE FactSet Global Genomics and Immuno Biopharma Index

Holdings

By weight

Concentration

Top 10 holdings = 64.3% of fundconcentrated

BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares

21.0%

REVOLUTION MEDICINES, INC.

6.9%

MODERNA, INC.

6.3%

IPSEN SA

5.2%

Bayer Aktiengesellschaft

4.4%

Takeda Pharmaceutical Company Limited

4.2%

MERCK & CO., INC.

4.1%

GSK PLC

4.1%

BioNTech SE

4.1%

Roche Holding AG

4.0%

Asset allocation

Stocks

99.8%

Cash

0.2%

By sector

Healthcare

100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years

Volatility (1Y)

28.6%High

Year-on-year price swings

Max drawdown

-68.3%Severe

Worst peak-to-trough loss

Sharpe (3Y)

0.77Decent risk-adjusted returns

Sortino (3Y)

1.18Good downside protection

Listing

Exchange: NYSE Arca

Full fund details

Objective: Tracks the investment results of an index composed of developed and emerging market companies benefiting from growth in genomics, immunology, and bioengineering.
Strategy: Seeks to track the NYSE FactSet Global Genomics and Immuno Biopharma Index, which includes large-, mid-, and small-cap companies in the biopharmaceutical and healthcare sectors. Focuses on firms with significant revenue from genomics and immunology, aiming for long-term growth and innovation.
Inception date: June 11, 2019
Fund family: iShares